Praxis Precision Secures $621M From Public Offering
Praxis Precision Medicines said its recent public offering generated about $621 million in net proceeds, and on January 12 Wedbush analyst Laura Chico raised the price target to $95 from $83 while maintaining an Underperform rating. The stock has gained over 420% in three months, and Wall Street consensus lists a Strong Buy with a one-year average target of $456.71. The company plans two FDA NDA submissions in February and multiple readouts over the next 12–24 months.
Key Points
- 1Raised price target to $95 after $621M public offering on Jan. 12
- 2Highlights market valuation variance: Wedbush sees 66% downside versus Street's 65% upside
- 3Signals imminent catalysts: two FDA NDA submissions and multiple readouts within 12–24 months
Scoring Rationale
Moderate investor relevance and confirmed offering; limited industry impact and company-specific focus reduce broader significance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems
